ZyVersa Therapeutics (ZVSA) Competitors $0.70 -0.01 (-1.89%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.71 +0.01 (+1.56%) As of 04/17/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVSA vs. DWTX, PHIO, NLSP, BTAI, CANF, TCRT, DRMA, ADIL, SNGX, and ONCOShould you be buying ZyVersa Therapeutics stock or one of its competitors? The main competitors of ZyVersa Therapeutics include Dogwood Therapeutics (DWTX), Phio Pharmaceuticals (PHIO), NLS Pharmaceutics (NLSP), BioXcel Therapeutics (BTAI), Can-Fite BioPharma (CANF), Alaunos Therapeutics (TCRT), Dermata Therapeutics (DRMA), Adial Pharmaceuticals (ADIL), Soligenix (SNGX), and Onconetix (ONCO). These companies are all part of the "pharmaceutical products" industry. ZyVersa Therapeutics vs. Dogwood Therapeutics Phio Pharmaceuticals NLS Pharmaceutics BioXcel Therapeutics Can-Fite BioPharma Alaunos Therapeutics Dermata Therapeutics Adial Pharmaceuticals Soligenix Onconetix ZyVersa Therapeutics (NASDAQ:ZVSA) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership. Which has preferable valuation and earnings, ZVSA or DWTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZyVersa TherapeuticsN/AN/A-$98.30MN/AN/ADogwood TherapeuticsN/AN/A-$5.30M-$11.34-0.38 Is ZVSA or DWTX more profitable? Dogwood Therapeutics' return on equity of -217.12% beat ZyVersa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ZyVersa TherapeuticsN/A -224.85% -103.22% Dogwood Therapeutics N/A -217.12%-172.06% Does the MarketBeat Community believe in ZVSA or DWTX? ZyVersa Therapeutics received 3 more outperform votes than Dogwood Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformZyVersa TherapeuticsOutperform Votes3100.00% Underperform VotesNo VotesDogwood TherapeuticsN/AN/A Does the media prefer ZVSA or DWTX? In the previous week, Dogwood Therapeutics had 4 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 5 mentions for Dogwood Therapeutics and 1 mentions for ZyVersa Therapeutics. ZyVersa Therapeutics' average media sentiment score of 0.42 beat Dogwood Therapeutics' score of 0.06 indicating that ZyVersa Therapeutics is being referred to more favorably in the media. Company Overall Sentiment ZyVersa Therapeutics Neutral Dogwood Therapeutics Neutral Which has more volatility & risk, ZVSA or DWTX? ZyVersa Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Dogwood Therapeutics has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500. Do insiders and institutionals believe in ZVSA or DWTX? 3.9% of ZyVersa Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 0.3% of ZyVersa Therapeutics shares are held by insiders. Comparatively, 12.2% of Dogwood Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryDogwood Therapeutics beats ZyVersa Therapeutics on 6 of the 9 factors compared between the two stocks. Get ZyVersa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVSA vs. The Competition Export to ExcelMetricZyVersa TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.80M$6.44B$5.30B$7.34BDividend YieldN/A3.23%5.12%4.30%P/E RatioN/A6.8921.8617.80Price / SalesN/A230.57380.5497.75Price / CashN/A65.6738.2634.64Price / Book0.015.936.453.98Net Income-$98.30M$142.99M$3.22B$247.81M7 Day Performance-9.21%4.43%2.85%1.80%1 Month Performance-5.85%-12.72%-8.67%-6.81%1 Year Performance-88.83%-9.42%11.46%1.31% ZyVersa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVSAZyVersa Therapeutics0.9731 of 5 stars$0.70-1.9%N/A-88.0%$1.80MN/A0.002Short Interest ↓DWTXDogwood TherapeuticsN/A$4.05-4.7%N/AN/A$5.40MN/A-0.625PHIOPhio Pharmaceuticals2.5843 of 5 stars$1.04-2.8%$4.00+284.6%-52.7%$5.11MN/A-0.1010NLSPNLS PharmaceuticsN/A$1.42-4.2%N/A+997.7%$5.11MN/A0.006Short Interest ↓Positive NewsGap UpBTAIBioXcel Therapeutics3.5082 of 5 stars$1.56-4.3%$42.60+2,630.8%-95.8%$5.00M$2.27M-0.0590Positive NewsCANFCan-Fite BioPharma2.1623 of 5 stars$1.41-4.1%$14.00+892.9%-38.8%$4.99M$667,000.00-0.798Analyst ForecastNews CoverageGap DownTCRTAlaunos Therapeutics0.6936 of 5 stars$3.00+1.7%N/A-80.0%$4.80M$10,000.000.0040High Trading VolumeDRMADermata Therapeutics1.8987 of 5 stars$0.88-7.9%$6.00+578.7%-83.5%$4.80MN/A-0.058Short Interest ↑News CoverageGap DownADILAdial Pharmaceuticals2.3595 of 5 stars$0.72+13.7%$8.00+1,011.1%-70.4%$4.73MN/A-0.2220SNGXSoligenix1.4839 of 5 stars$1.87+1.6%N/A-74.3%$4.69M$840,000.00-0.2520Short Interest ↓Gap UpONCOOnconetix0.9459 of 5 stars$0.07flatN/A-98.8%$4.65M$1.87M0.0012Short Interest ↓Gap Down Related Companies and Tools Related Companies DWTX Alternatives PHIO Alternatives NLSP Alternatives BTAI Alternatives CANF Alternatives TCRT Alternatives DRMA Alternatives ADIL Alternatives SNGX Alternatives ONCO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVSA) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?Recently, President Trump decided to kill the coin, for good reason. It now costs 4 cents to make a single pen...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZyVersa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
